

## Edwin Janssen

Bergschot 71, 4817PA Breda, The Netherlands | +31 76 573 7574

EdwinJanssen@eurofins.com

### Profile

*Dr. Edwin Janssen is trained as a molecular cell biologist and has been the Global Science Director since February 2016 at Eurofins Central Laboratory. He previously served as director of the Biomarker and Biopharmaceutical Laboratory (2008-2013) and Head Scientific affairs (2014-2016). Before joining Eurofins, he gained several years of postdoctoral experience in cell tumor metabolism at the Department of Cell Biology (NCMLS), Radboud University. He has been a visiting research fellow at Mayo Clinic (Rochester, MN), during which he was awarded NWO Horizon Grant and NCMLS price for best thesis.*

*Dr. Edwin Janssen joined the Pharma Industry in 2005. At Schering-Plough (formerly Organon), he managed research contracts, participated in lead-finding and lead-optimization teams, and was a group leader within the proteomics and genomics section, focusing on the development and implementation of biomarkers in lead programs and proof of concept studies. He was also group leader within the oncology section, leading projects on kinase inhibition and identification of PD biomarkers. He has been a member of working groups on proteomics among pharma companies and has been a member of the European Bioanalytical Forum. He has published in peer-reviewed journals, such as PNAS, EMBO J., Nat. Biotech, and has spoken nationally and internationally on the topics of metabolism, immunogenicity, clinical biomarkers and related therapeutic areas.*

*Currently, Dr. Janssen is the Global Science Director/Chief Scientific Officer where he is responsible for the overall direction of the scientific and analytical aspects within Eurofins Central Laboratories in accordance with all standards and regulations governing clinical laboratories throughout the world. Since April 2015, Dr. Janssen is the Laboratory director for the College of American Pathologists' (CAP) Laboratory Accreditation Program for the EU laboratory in the Netherlands and since March 2013, Dr. Janssen is the OECD GLP Test facility manager for the EU laboratory in the Netherlands.*



## Professional Experience

**Feb 2016 - Present**

### **Global Science Director/Chief Scientific Officer**

- Responsible for the overall direction of the scientific and analytical aspects within Eurofins Central Laboratories (ECL) in accordance with all standards and regulations governing clinical laboratories throughout the world.

**April 2015 - Present**

### **CAP Laboratory Director EU Clinical Laboratory**

- Responsibility for the College of American Pathologists' (CAP) Laboratory Accreditation Program for ECL Breda, the Netherlands
- Approval French Research Tax Credit, Crédit d'impôt recherché (CIT) 2015-2017, 2018 -2020
- Approval Opiates license (Dutch Authority CIBG)
- Approval GMO license (Dutch Authority Bureau GGO)
- Approval Radionucleotide laboratory license (Dutch Authority ANVS)

**Mar. 2013 - Present**

### **GLP Test facility Manager**

- Assignment of staff for each study (GLP or "spirit of GLP") with the appropriate qualifications, training and experience (Study Director)
- Provide for development plan and on-going training of personnel in field of regulated Biomarker analysis
- Review/update/approve SOPs in line with business principles and applicable regulations (OECD GLP, GCP, CAP, ISO 17025, ISO15189).

**March 2014 – Jan 2016**

### **Head Scientific Affairs**

- Take a lead role in the decision process for when, how, and where to bring up new assays or capabilities (CAPEX, yearly budgets).
- Provide scientific and regulatory expert support for the global Operation (and Client) teams
- Active Member European Bioanalytical Forum (EBF)
- Responsible for Clinical Biomarker Analytical Services and strategy at Eurofins Central Laboratory.



**Feb. 2013 – March 2014**

**Scientific Affairs Manager Clinical Biomarkers and SAC member  
Co-founder Eurofins Scientific Affairs Council (SAC).**

- Overseeing business development strategies, activities and transactions on biomarker applications in (pre)clinical trials.
- Provide expert oversight for Biomarker projects at Eurofins Central Laboratory.
- Member European Bioanalytical Forum (EBF), EBF Topic team lead on Parallelism.
- Responsible for WBSO subsidiary applications, WBSO project administration, and inspection.

**Dec 2008 – June 2013**

**Head Biomarker and Biopharmaceutical group;  
Eurofins Central Laboratory.**

- Established and expanded Bioanalytical capabilities on Biopharmaceuticals (PK-Immunogenicity) and Biomarkers according to FDA/EMA regulations.
- Composed yearly budget, responsible for internal P&L for group of 19 FTE's.
- Managed staff performance, set objectives in line with annual plan, performed regular reviews, provided corrective actions.
- Hired qualified staff, replaced underperforming employees
- Established procedures, KPIs/metrics to improve operational performance of the Biomarker/ Biopharmaceutical laboratory
- CAPEX/ROI Investments in line with business progression and strategy
- Established cell culture lab and relevant license (Milieuvergunning)
- Instrumental in business line transfer to other Eurofins partner laboratories
- Provided expert oversight including tech transfer for pharma projects on biomarkers at Eurofins lab Shanghai , China.



- April 2007 – Nov. 2008**      **Group leader, LO-team member, Oncology section, Target Discovery, Organon/Schering-Plough.**
- Dec. 2005 – March 2007**      **Group leader, LO-team member, proteomics and genomics section, Target Discovery, Organon. Project leader external collaboration Dutch Proteomic Centre.**
- Oct. 2002 – Nov. 2005**      **Post-doc, Department of Cell Biology, The Nijmegen Centre for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen. Supervision team of technicians.**
- July 1998 – July 2002**      **Ph.D. Student, Department of Cell Biology, The Nijmegen Centre for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen.**  
*Included: residency of 6 months, Research fellow, Mayo Clinic, Rochester, USA.*
- July 1995 – July 1998**      **Research assistant, Department of Cell Biology, The Nijmegen Centre for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen.**

### Education and Training

1998 – 2002

*Doctorate, University, The Nijmegen Center for Molecular Life Sciences, Nijmegen.*

*Thesis: The role of Adenylate Kinase 1 in energy transfer: A study of mice lacking Adenylate kinase 1. Promotor: Prof. Dr. B. Wieringa. Doctorate diploma: 2003.*

### Publications

- Janssen, E., Dzeja, P. P., Oerlemans, F., Simonetti, A. W., Heerschap, A., de Haan, A., Rush, P. S., Terjung, R. R., Wieringa, B., and Terzic, A. (2000) *EMBO J* 19, 6371-6381.
- Pucar, D., Janssen, E., Dzeja, P. P., Juranic, N., Macura, S., Wieringa, B., and Terzic, A. (2000) *J Biol Chem* 275, 41424-41429.
- de Groof, A. J., Smeets, B., Groot Koerkamp, M. J., Mul, A. N., Janssen, E. E., Tabak, H. F., and Wieringa, B. (2001) *FEBS Lett* 506, 73-78.
- Carrasco, A. J., Dzeja, P. P., Alekseev, A. E., Pucar, D., Zingman, L. V., Abraham, M. R., Hodgson, D., Bienengraeber, M., Puceat, M., Janssen, E., Wieringa, B., and Terzic, A. (2001) *Proc Natl Acad Sci USA* 98, 7623-7628.



- Makarchikov, A. F., Wins, P., Janssen, E., Wieringa, B., Grisar, T., and Bettendorff, L. (2002) *Biochim Biophys Acta* 1592, 117-121.
- Pucar, D., Bast, P., Gumina, R. J., Lim, L., Drahl, C., Juranic, N., Macura, S., Janssen, E., Wieringa, B., Terzic, A., and Dzeja, P. P. (2002) *Am J Physiol Heart Circ Physiol* 283, H776-782.
- Janssen, E., de Groof, A., Wijers, M., Fransen, J., Dzeja, P. P., Terzic, A., and Wieringa, B. (2003) *J Biol Chem* 278, 12937-12945.
- Janssen, E., Terzic, A., Wieringa, B., and Dzeja, P. P. (2003) *J Biol Chem* 278, 30441-30449.
- Janssen, E., Kuiper, J., Hodgson, D., Zingman, L. V., Alekseev, A. E., Terzic, A., and Wieringa, B. (2004) *Mol Cell Biochem.* 256-257, 59-72.
- Hancock, C., Janssen, E., Terjung, R. (2005) *Am J Physiol Cell Physiol* 288, 1287-97.
- Hancock, C., Janssen, E., Terjung, R. (2006) *J Appl Physiol.* 100, 406-13.
- Willemse M, Janssen E., de Lange F., Wieringa B., Fransen J. (2007) *Nat Biotechnol.* 25, 170-2.
- van Horssen R, Janssen E, Peters W, van de Pasch L, Lindert MM, van Dommelen MM, Linszen PC, Hagen TL, Fransen JA, Wieringa B. (2009). *J Biol Chem.* 1620-7.
- Kuiper JW, van Horssen R, Oerlemans F, Peters W, van Dommelen MM, te Lindert MM, ten Hagen TL, Janssen E, Fransen JA, Wieringa B. (2009). *PLoS One.* 4, 5030.
- Hageman, S and Janssen E. (2009). *International Clinical Trials.* 6, 59-61.
- Janssen E. NGP Round Table on Biomarker Technologies (2010). *Next Generation Pharmaceutical EU Magazine.* 9, 102-106
- Janssen E (2013). *International Clinical Trials.* ICT summer 2013, 18-21.

### Grants and Awards

- NWO Horizon project: "Identification and combinatorial use of allosteric binding modules for intracellular biosensors", registration nr. 050-71-102, October 2004 – April 2006. Project leader E. Janssen.
- NCMLS award 2004. Price for best PhD thesis 2003, entitled: "The role of Adenylate kinase 1 in energy transfer: A study of mice lacking Adenylate kinase 1".

Edwin Janssen

Digitally signed by Edwin Janssen  
Date: 2020.06.17 13:37:36 +02'00'

Signature / Date: \_\_\_\_\_

